Medical device stocks of all kinds were pummeled over the past week as investors tried to calculate the ripple effects of new weight loss drugs. It wasn’t the first rout in the sector — the pressure has persisted for several months. The fear has been that whenever you have a large group of consumers changing…
A doctor vaccinates an infant against respiratory syncytial virus (RSV) in a treatment room of her paediatric practice. Swen Pförtner | Picture Alliance | Getty Images The Centers for Disease Control and Prevention on Friday recommended Pfizer‘s maternal vaccine that protects infants from respiratory syncytial virus, putting the shot on track to be available in the U.S. this fall….
The Amgen logo is displayed outside Amgen headquarters on May 17, 2023 in Thousand Oaks, California. Mario Tama | Getty Images The Federal Trade Commission on Friday said it has reached a deal with drug giant Amgen to allow the company’s $27.8 billion purchase of Horizon Therapeutics to move forward. The two companies now expect…
Read More “FTC allows Amgen to move forward with $27.8 billion Horizon Therapeutics acquisition” »
A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. Jim Vondruska | Reuters Novo Nordisk, which makes the weight-loss drug Wegovy, raised its outlook for 2023 Thursday, as it reported soaring sales. The Danish pharmaceutical company reported a 30% increase…
Read More “Wegovy-maker Novo Nordisk raises outlook as sales of its weight-loss drug soar” »
Thibaut Mongon, CEO of Kenvue Inc. a Johnson & Johnson’s consumer-health business, speaks during an interview to celebrate its IPO at the New York Stock Exchange (NYSE), May 4, 2023. Brendan Mcdermid | Reuters Most consumers have pulled back on spending as inflation squeezes their wallets, but they have not stopped paying up for brand-name…
The Alzheimer’s drug Leqembi is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai | via Reuters Medicare has agreed to pay for the Alzheimer’s treatment Leqembi, a major turning point for patients who are diagnosed with the early stages of the disease. Leqembi is the only drug on the…
Read More “Medicare will pay for Alzheimer’s drug Leqembi. What patients and doctors should know” »
